CN Patent

CN113214261A — 一种依鲁替尼晶型a的纯化方法

Assigned to SYNCOZYMES (SHANGHAI) CO Ltd · Expires 2021-08-06 · 5y expired

What this patent protects

本发明公开了一种依鲁替尼晶型A的纯化方法，该方法为利用晶型转化实现依鲁替尼晶型A的纯化，具体过程为将依鲁替尼晶型A粗品溶解、加入晶种E后得到依鲁替尼晶型E，再将晶型E溶解、结晶得到纯度更高的依鲁替尼晶型A。本发明所述的依鲁替尼晶型A的纯化方法工艺简单、产率高，解决了依鲁替尼结晶A中难除杂质的纯化问题。

USPTO Abstract

本发明公开了一种依鲁替尼晶型A的纯化方法，该方法为利用晶型转化实现依鲁替尼晶型A的纯化，具体过程为将依鲁替尼晶型A粗品溶解、加入晶种E后得到依鲁替尼晶型E，再将晶型E溶解、结晶得到纯度更高的依鲁替尼晶型A。本发明所述的依鲁替尼晶型A的纯化方法工艺简单、产率高，解决了依鲁替尼结晶A中难除杂质的纯化问题。

Drugs covered by this patent

Patent Metadata

Patent number
CN113214261A
Jurisdiction
CN
Classification
—
Expires
2021-08-06
Drug substance claim
No
Drug product claim
No
Assignee
SYNCOZYMES (SHANGHAI) CO Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.